Abstract
The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.
| Original language | English |
|---|---|
| Pages (from-to) | 47-57 |
| Number of pages | 11 |
| Journal | Pharmaceutical Patent Analyst |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2018 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- immunotherapeutics
- immunotherapy
- metastatic castration-resistant prostate cancer (mCRPC)
Fingerprint
Dive into the research topics of 'Immunotherapeutics for the treatment of prostate cancer: A patent landscape based on key therapeutic mechanisms of actions'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver